Machado-Alba, J. E. http://orcid.org/0000-0002-8455-0936
Machado-Duque, M. E. http://orcid.org/0000-0001-8458-0986
Gaviria-Mendoza, A. http://orcid.org/0000-0003-2500-7658
Arsof-Saab, I. N.
Castellanos-Moreno, C. A.
Botero, L.
Triana, L.
Funding for this research was provided by:
Sanofi Colombia S.A and IPSEN Export Latin America (E003183552)
Technological University of Pereira
Article History
Received: 5 May 2022
Accepted: 17 July 2022
First Online: 1 August 2022
Declarations
:
: LB, LT, CC are employees of Sanofi-Aventis Colombia, and may hold shares and/or stock options in the company. IA is an employee of Ipsen. JEMA, AGM and MEMD are employees of Audifarma and Universidad Tecnologica de Pereira and do not have any other conflict of interest.
: The protocol was approved by the Bioethics Committee of the Universidad Tecnológica de Pereira (Technological University of Pereira) in the category of risk-free research (Code: 20 - 150321). The ethical principles established by the Declaration of Helsinki were respected.
: The information was obtained from an administrative database. According to Colombian regulations (Resolution 8430 of 1993 of the Ministry of Health) for risk-free research in which patients are not interviewed, it is not required to sign an informed consent.